Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial

Shenghua Zhou,Yichao Xiao, Chonglun Zhou,Zhaofen Zheng,Weihong Jiang, Qiang Shen, Can Zhu,Hongwei Pan,Changhui Liu,Gaofeng Zeng,Liangqing Ge,Yumin Zhang,Zewei Ouyang,Guang Fu,Gang Pan,Feng Chen,Lihong Huang,Qiming Liu

JAMA network open（2023）

引用 3|浏览51
暂无评分
关键词
acute coronary syndrome,enoxaparin,major cardiac adverse events,rivaroxaban,bleeding risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要